Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim of our study is to evaluate liver fibrosis using biochemical markers, FibroScan, and radiology methods in patients with chronic hepatitis B in mainland China.
Condition or disease
Chronic Hepatitis B
Up to Nov, 2015, total of 818 patients with chronic HBV infection had been enrolled in the study. Paired blood and liver biopsy specimen had been collected. The serum samples stored at -80 degree Celsius. All the liver biopsy samples were judged by three pathology experts, according to Ishak standard.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patients with chronic hepatitis B or compensated cirrhosis due to chronic hepatits B virus (HBV) infection
clinical diagnosis of chronic hepatitis B or compensated cirrhosis due to chronic hepatitis B virus infection
agree to have liver biopsy
clinical diagnosis of decompensated cirrhosis due to hepatitis B virus or inactive carrier